DIAMONTECH MEDIA PRESENTATION
A Game Changer in health care diagnostics with unique laser-based technology
for non-invasive blood glucose measurement
October 2019
DISCLAIMER
THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF
AMERICA, AUSTRALIA, CANADA OR JAPAN.
This presentation and all ancillary documents relating to it were prepared for preliminary feedback discussions in relation to Diamontech GmbH (“Company”) and in particular must not be
used in making any investment decision. All material contained in this presentation and information presented is in summary form for preliminary discussion purposes only and must not be
relied upon for any purpose, and does not purport to be a full or complete description of the Company. The information in this presentation reflects current conditions and judgment of the
Company as of this date, all of which are subject to change or amendment without notice and the delivery of such amended information at any time does not imply that the information
(whether amended or not) contained in this presentation is correct as of any time subsequent to its date. Accordingly no representation or warranty, express or implied, is made as to the
fairness, accuracy, adequacy, completeness or correctness of such information, nor as to the achievement or reasonableness of any projections, targets, estimates, or forecasts and nothing
in this presentation should be relied upon as a promise or representation as to the future.
MainFirst (the “Bank”) has independently verified any information herein. The Bank is acting only for the Company in setting up meetings for the presentation and will not be responsible to
anyone other than the Company for providing the protections afforded to clients of such Bank or for providing advice in relation to any potential investment in the Company.
Neither the Company nor any of the Bank, nor any of their respective officer or employees nor any person connected with any of them, accepts any liability whatsoever for any direct,
indirect or consequential damages or losses arising from any use of this presentation or its contents or otherwise arising in connection therewith. Neither the Company nor the Bank
undertakes any obligation to update or correct any information contained herein or to otherwise advise as to any future changes to it.
The information in this presentation may include forward-looking statements, which are based on current expectations and projections about future events. These forward-looking
statements, as well as those included in any other material forming part of the preliminary feedback discussions, are subject to risks, uncertainties and assumptions about the Company,
including, amongst other things, the development of its business and product and development pipeline. In light of these risks, uncertainties and assumptions, the events in the forwardlooking statements may not occur. No one undertakes to publicly update or revise any such forward-looking statement.
This presentation is non-binding and only for information purposes; there was no independent verification of the contents of this presentation. It is not and shall not be construed as an
offer, invitation, recommendation or solicitation to sell, issue, purchase or subscribe for any securities of the Company in any jurisdiction or to enter into any transaction. This presentation
should not be construed as a prospectus or offering presentation and investors should not invest in the Company on the basis of or in reliance on the information in this presentation.
This presentation does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, or the United States of
America or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein may not be offered or sold in the United States of America absent
registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements
of the Securities Act. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any
national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to herein has not been and will not be registered under the Securities Act or under the
applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States of America. Any participant in meetings for this presentation in the
United States of America, by its participation, is deemed to have represented that it is a “accredited investor” as defined in Rule 501 under the Securities Act.
This presentation is only addressed to and directed at persons in member states of the European Economic Area who are “qualified investors” within the meaning of Article 2(e) of the
Prospectus Regulation (Regulation (EU) 2017/1129). This presentation must not be acted on or relied on in any member state of the European Economic Area by persons who are not
qualified investors.
This presentation is directed at and/or for distribution in the United Kingdom only to (i) persons who have professional experience in matters relating to investments falling within article
19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (ii) high net worth entities falling within article 49(2)(a) to (d) of the Order (all such
persons are referred to herein as “relevant persons”). This presentation is directed only at relevant persons. Any person who is not a relevant person should not act or rely on this
presentation or any of its contents. Any investment or investment activity to which this presentation relates is available only to relevant persons and will be engaged in only with relevant
persons.
By accessing this presentation, you represent, warrant and undertake that you have read and agree to comply with and to be bound by the contents of this disclaimer.
2
DIAMONTECH GMBH | MEDIA PRESENTATION
OUR MISSION & VISION
Health-care revolution in the making – reagent-free diagnostics
THE CHALLENGE
“The delivery of health care has proceeded for decades with a blind spot: Diagnostic
errors - inaccurate or delayed diagnoses - persist throughout all settings of care and
continue to harm an unacceptable number of patients.”
National Academies of Sciences, Engineering, and Medicine (2015): “Improving diagnosis in health care.“
OUR MISSION
OUR VISION
Diagnostics will play an increasingly important role
in the development of the healthcare market. We
aim to offer the fastest, most convenient and most
accurate diagnostic applications in the industry –
helping to create a future where we can almost
continuously monitor our health.
Our vision is to replace current reagent-based
diagnostics with our technology in labs and at
home.
We aim to become the global market leader for
non-invasive blood glucose monitoring over the
coming years.
3
DIAMONTECH GMBH | MEDIA PRESENTATION
OUR GROUND-BREAKING TECHNOLOGY
The world’s first laser-based non-invasive measurement of blood glucose
Key Technological Highlights
Operating Principle
• IRE-PTD-Spectroscopy* is a new and universal platform
technology in infrared spectroscopy
• The technology is designed to detect molecules in liquids
and soft matter (e.g. skin)
• The technology combines high selectivity with high
simplicity and efficiency
• IRE-PTD-Spectroscopy offers a multitude of potential
application fields across industries
• Strong patent protection for the IRE-PTD-base
technology
• An external cavity quantum cascade laser emits light in
the mid-infrared spectrum, leading to oscillation of
glucose molecules in the interstitial fluid of the skin
• As a result a small amount of heat is produced in the
analyte’s skin, e.g. in the fingertip, and transferred to the
measuring crystal
• The slight heating changes the optical properties of the
crystal
• A second laser beam is deflected on a detector unit as a
result
*IRE-PTD-Spectroscopy = Internal Reflection Element with PhotoThermal Detection
4
DIAMONTECH GMBH | MEDIA PRESENTATION
OUR PRODUCT ROADMAP
Best-in-class consumer product to be launched by end of 2020
2018
End of 2020
2023/24
D-BASE
D-POCKET
D-BAND*
Shoebox-sized device to conduct
human trials with our technology.
Pocket-sized personal device for the
individual end user for day and
night.
Wearable device (wrist band) that
continuously measures blood
glucose.
This helps users track blood sugar
levels more frequently without
fingerpicking or reagents. This
includes data logging and alarm
functions to track glucose levels.
This includes data logging and alarm
functions to track glucose levels.
In clinical tests, we achieved an
accuracy comparable to test strips.
CE certified since March 2019.
* DiaMonTech does not intend to produce the wearable device as such, but rather to supply the glucose measuring components/technology to the producer of the wearable
device or smart watch.
5
DIAMONTECH GMBH | MEDIA PRESENTATION
ACCURACY
Our latest clinical study confirmed high accuracy on par with traditional invasive methods
Test Results* of „Study 100“
Consensus Error Grid Analysis
• Test compares non-invasive results from our
photothermal glucometer versus results from a clinical
grade invasive system (HemoCue® Blood Glucose
Analyser)
• Results are plotted in a “Consensus Error Grid”, the gold
standard to determine accuracy of new glucometers
• 99%+ of measurement results without or with little
deviation from clinical outcome (Regions A and B)
demonstrate a high level of accuracy
• Clear outperformance over any other non-invasive
products/concepts known to us
• Our technology and results are published in peerreviewed scientific journals, e.g.: Depth-selective
photothermal IR spectroscopy of skin: potential
application for non-invasive glucose measurement.
Analyst. 2017;142(3):495–502.
• 1,943 data points
• 100 test persons:
• 59 healthy
• 41 diabetic
Region A: 84.7%
Region B: 14.4%
Region C: 0.9%
Region D: 0.0%
Region E: 0.0%
* The results shown herein do not include low quality data detected and discarded by the application of an improved algorithm to all measured data.
6
DIAMONTECH GMBH | MEDIA PRESENTATION
These results
are “accurate”
WHY IT WORKS
Key facts on our technology and approach
Measurement is taken in the
interstitial fluid of the skin
Highly selective ‚fingerprint‘ of
the glucose molecule
Pulsed quantum cascade lasers
(QCL)
Patented Photothermal
detection (IRE-PTD)
High specificity for glucose
molecule due to specific tuning
of the EC-QCL
Spectroscopy in the mid-IR
(approx. 7-11 µm)
7
DIAMONTECH GMBH | MEDIA PRESENTATION
KEY PRODUCTS
DiaMonTech is uniquely positioned
Invasive
Minimal-Invasive
Non-Invasive
Company
Product/
Technology
Accu-Chek
Eversense / CGMSystem
Freestyle Libre /
FGM-System
Dexcom G6
GlucoTrack
D-Pocket
Application
Teststrip device, needs
drop of blood
Implant (every 3-6
months)
Patch with tiny needle
(every 10-14 days)
Patch with tiny needle
(every 10 days)
Earlobe-clip
Hold finger on
sensor for some
seconds
Measurement
Method
Electrochemical (test
strip with reagents)
Electrochemical
(implant with
reagents)
Electrochemical
(micro-needle and
reagents)
Electrochemical
(micro-needle and
reagents)
Ultrasonic,
Electromagnetic,
Thermal
Mid infrared
photothermal
detection
Accuracy
98%+
98%+
98%+
98%+
‘Only Type-2
diabetics’
99%+
Price/Costs of
Therapy*
949 EUR p.a. (4 tests
per day)
5,400 EUR p.a.
1,437 EUR p.a.
c. EUR 5,000 p.a.
n/a
1,200 EUR p.a.**
Units Sold
Millions p.a. (est.)
1,000 p.a. (est.)
800,000 p.a. (est.)
n/a
0
-
* Based on German Retail Pricing as of September 2019; * expected initial pricing for D-Pocket
8
DIAMONTECH GMBH | MEDIA PRESENTATION
MARKET OVERVIEW
DiaMonTech’s first product targets a well organised, established & sizeable market
Global Blood Glucose Monitoring Systems Market Forecast (invasive)*
Comments
USD 16,bn
• Availability of non-invasive products is
expected to remain limited
USD 12,bn
• Population of Diabetes patients is expected to
keep growing
USD 8,bn
• With regards to market volume, we currently
expect production of D-Pocket being the
limiting factor, not overall demand
USD 4,bn
USD ,bn
2015
2016
2017
2018 2019e 2020e 2021e 2022e 2023e 2024e 2025e 2026e
Global Blood Glucose Monitoring Systems Market Forecast (non-invasive)*
USD 2,5bn
USD 2,bn
“Diamontech is developing a pocket-sized blood
sugar measurement device which can be carried along
anytime. These upcoming products are anticipated to
drive the non-invasive segment growth.”*
USD 1,5bn
USD 1,bn
USD ,5bn
• Currently lack of available non-invasive
products on the market
• Fortune Business Insights independently
chose to cite DiaMonTech‘s D-Pocket to
justify its expectation of a ramp-up in the noninvasive segment in the near future
• We aim to be the first mover in this market
USD ,bn
2015
2016
2017
2018 2019e 2020e 2021e 2022e 2023e 2024e 2025e 2026e
* Source: Fortune Business Insights – Blood Glucose Monitoring Systems Market Study 2019
9
Comments
DIAMONTECH GMBH | MEDIA PRESENTATION
MARKET OVERVIEW
Number of diabetics expected to grow to over 600 million people
Number of diabetics worldwide 2000-2045e
(in million)
415
366
628
425
382
285
246
194
=
151
2000
* Source: International Diabetes Federation
10
DIAMONTECH GMBH | MEDIA PRESENTATION
2009
2013
2017
2045
STRATEGIC COOPERATIONS
Strategic Development and Sales Cooperations with two of the largest Health Care
Organisations in Germany
DAV (German Association of Pharmacies)
Top-3 German health insurance company
• Sales cooperation*
• Product development and diabetes screening
cooperation*
• DAV is umbrella organization of around 19,000
pharmacies in Germany
• Target: Give patients access to latest technology via
pharmacies and improve the care of diabetes patients
• First Step: Practical tests of the CE-certified ‘D-Base’ in
selected pharmacies in Germany
• Second step: Marketing of ‘D-Pocket’ via DAV pharmacy
network
* So far intention to cooperation documented by legally non-binding LoIs
11
DIAMONTECH GMBH | MEDIA PRESENTATION
• One of the largest statutory health insurances in Germany
• Target: Early detection and diabetes screening
• First Step: Starting H1 2020 set up “D-Base” at selected
health insurance company locations
• Second step: Roll out of diabetes screening program to
identify pre-diabetics in up to three states
• Third step: National roll-out
THE ARENA WE ENTER
The market is not only sizeable but also appears to be receptive for new, innovative
products
High Interest of Distributors
• For the distribution outside of Europe, DiaMonTech will
work with partners
• LOI with distributor signed for China:
100k units p.a. @ USD 2,000 – USD 2,500 per device
• LOI with distributor signed for Japan:
10k p.a. @ USD 2,000 – USD 2,500 per device
• Key markets: USA, China, Japan, LatAm
Market Volume Blood Glucose Monitoring (invasive)*
2026:
USD 14.7 billion
2019:
USD 10.8
billion
2019 – 2026
CAGR of 4.5%*
Self-Distribution
Quick take-up expected
• Self distribution planned in Europe and co-operation with
selected partners
• Planned distribution channels: e-commerce via website
(like „FreeStyle Libre Pro System“) and partnerorganisations (e.g. pharmacies)
• LoIs signed with top three German insurance company
and umbrella organization of all pharmacies in Germany
• Key markets: Benelux, France, Germany, Italy and Spain
• Minimal-invasive product Freestyle Libre was introduced
in the US in September 2017 (FDA approval)
• Expected 2019 sales of Freestyle Libre: USD 1.5 billion
• Abbott reported a stellar 73% growth rate for sales of its
Freestyle Libre system specifically (Q2 2019)
* Source: Fortune Business Insights – Blood Glucose Monitoring Systems Market Study 2019
12
DIAMONTECH GMBH | MEDIA PRESENTATION
These results are
“accurate”
ADDITIONAL FUTURE OPPORTUNITIES
DiaMonTech is far from a one-trick-pony
INVESTMENT CASE
FREE-OPTIONS FOR FUTURE GROWTH
Non-Invasive Blood Glucose
Monitoring
Blood Analysis without
Reagents
Urine Analysis without
Reagents
Drug Monitoring in Blood
without Reagents
Successful clinical study of
technology platform
Instant blood test
Revolutionizing urinalysis
New solutions for “real-time”
therapeutic drug monitoring
Product
Non-invasive blood glucose
measurement
“Instant blood test”
“Real time” urine analysis
“Real-time” therapeutic drug
measurement in blood
Time-to-market
• Pocket size device by end
of 2020
• Wrist band in 2023/24
• Test device in lab available
• More biomarkers every
year
• Same device as for blood
testing with different
sensor
• Research phase
• First test results in 2021
Estimated mid-term
sales potential
Mid-triple digit millions
13
DIAMONTECH GMBH | MEDIA PRESENTATION
MANAGEMENT TEAM & FOUNDERS
Experienced Management with complementary skillsets revolving around high-tech
Thorsten Lubinski, Founder & CEO
Enrico Just, CFO
Computer Scientist with Diploma in
Business Administration & Serial
entrepreneur. Grew several startups
to millions in revenue. iLove (sold
together with Jamba for USD 273m
to Verisign); Plinga (Online-Gaming)
sold to OrangeGames.
Diploma in Business Economics;
successfully managed an IPO and a
merger of two publicly listed
companies. Co-Founder of several
start ups. >25 years’ experience in
senior management positions.
Prof. Dr. Werner Mäntele, Founder
Dr. Rainer Gith, Founder
Professor of Bio-Physics one of the leading experts in
molecular spectroscopy worldwide.
Accrued over 30 years of experience
in detecting molecules in liquids.
Owner of a law firm focused on
hardware startups, especially
financing and IP. Sold startup
„Secusmart“ to RIM in 2014.
14
DIAMONTECH GMBH | MEDIA PRESENTATION
CURRENT SHAREHOLDERS
Shareholder base supports growth strategy
Prof. Dr. Werner
Mäntele; 23.32%
Other*; 26.72%
Alexander Zahn; 3.04%
Christian Mäntele; 3.11%
Thorsten Lubinski;
21.77%
TD Verwaltungs GmbH; 3.19%
DS Invest GmbH / Rainer Gith; 3.63%
MOre Invest GmbH; 3.87%
Jindong Capital; 4.60%
* Composed of VC, Business Angels & High net worth individuals
15
DIAMONTECH GMBH | MEDIA PRESENTATION
Bioventure; 6.74%
MILESTONES
DiaMonTech’s roots reach back all the way to 1997
Publication of
clinical Study
Start of
Research &
Development
Transfer of
patents
from University
to DiaMonTech
1997
Q4 2019
Patent
granted for
improved Core
Technology
Start of Clinical
Study With
100 Persons
2016
2015
DiaMonTech’s
Foundation
2015
16
DIAMONTECH GMBH | MEDIA PRESENTATION
Further
Products
Starting
2023
2018
1st Tests
With 99.9%
Accuracy
in Laboratory
2016
CE Mark
D-Base
Won “Start
Me Up!” Award
2017
H1 2019
Market Launch
D-Pocket
End 2020
SUCCESS FACTORS
DiaMonTech is well positioned to act on an attractive market opportunity
Revolutionary
Diagnostics Platform
Wide Spectrum of
Applications
Intellectual Property
Secured
Fast Product
Development Process
DiaMonTech provides
unrivalled accuracy in noninvasive blood glucose
measurement.
The laser-based technology
platform can be used in
various healthcare and
other applications.
DiaMonTech currently has
various granted patents in
6 patent families and
numerous pending patents
worldwide.
All applications are based
on the same platform
technology. New products
can be developed
comparatively quickly.
Team with Leading
Experts
Combining Market &
Technology
Reliable and
Committed Partners
Contacts in Various
Countries
The team is composed of
leading experts in the fields
of physics, biology,
business and engineering.
DiaMonTech‘s lead product
has compellingly
demonstrated proof-ofconcept in clinical trials.
DiaMonTech is connected
with strong partners
supporting the business
development.
Excellent global
management network,
especially in Europe, USA,
Japan, and China.
17
DIAMONTECH GMBH | MEDIA PRESENTATION
MEDIA & AWARDS
Award-winning technology with international media coverage
Forbes.com
BILANZ Startup-Award
DIE WELT
„One of Europe's most exciting
technologies for 2018“
„And the winner for the best German
High-Tech-Startup in 2017 is:
DiaMonTech“
„An enormous relief for 420 million
diabetes patients worldwide“
BBC World News
Huffington Post
building better healthcare
3 minute live interview on „Business
Live: The inside track“
„As well as being non-invasive, the
technology is also fast“
„Breakthrough technology“
18
DIAMONTECH GMBH | MEDIA PRESENTATION
PRESS CONTACT
Kirchhoff Consult AG
Alexander Neblung
Phone: +49 40 60 91 86 70
E-mail: diamontech@kirchhoff.de